Pharming Group NV (EURONEXT:PHARM) Target Cut To €2.20; Buy Kept

Pharming Group (PHAR) reported positive Phase II results for Leniolisib in treating rare genetic immune disorders. The study showed improvements in spleen volume, lymph node size, lung function, and liver stiffness. The drug was well-tolerated, with no new safety concerns. PHAR stock closed at $9.44, down 1.77%.

Pharming Group N.V. (PHAR) reported positive Phase II trial results for Leniolisib in treating rare genetic immune disorders. The study showed improvements in immune dysregulation, spleen volume reduction, and disease markers. All participants opted for extended treatment. PHAR stock closed at $9.44, down 1.77%.

Pharming Group N.V. (PHARM) reported positive Phase II data for leniolisib in PIDs, showing improvements in spleen volume and lung function. The drug was well-tolerated, and all participants continued treatment. Topline CVID Phase II data is expected in November, potentially expanding the drug's market.

Pharming presented positive Phase II trial data for leniolisib in treating rare immune diseases. The drug showed improvements in spleen volume, lymph nodes, and lung function in 11 participants. All participants elected to continue treatment in an extension study. Pharming's shares trade on Euronext Amsterdam (PHARM) and Nasdaq (PHAR).

Pharming's CEO Fabrice Chouraqui stepped down due to strategic disagreements with the board. Leverne Marsh and Kenneth Lynard will serve as interim co-CEOs. Pharming lowered its 2026 revenue guidance to $375M-$395M and reported Q2 revenue of $90.2M, a 3% decrease year-over-year.

Pharming Group (PHAR) announced FDA acceptance of its sNDA for lower doses of Joenja in children aged 4+ with APDS, granted Priority Review with a PDUFA target date of Jan 30, 2027. The application is supported by positive Phase 3 study data. Joenja is currently approved for adults and pediatric patients aged 12+ with APDS. PHAR stock is up 0.27% at $10.47.